Abrégé

An isotope adsorbent of the present invention may comprise a base portion, pore channels formed as a plurality of holes in the base portion, first and second sorption sites positioned at a wall portion of each pore channel, and a third sorption site positioned in the central portion of the pore channel. An isotope separation method of the present invention may comprise the steps of: injecting an isotope mixture including a first element and a second element into an isotope adsorbent; allowing the first element or the second element to be adsorbed onto wall portions of the pore channels of the isotope adsorbent; and, when the second element, having a greater mass than the first element, is adsorbed onto the wall portions of the pore channels, allowing the second element to be further adsorbed onto the inside of the adsorbed second element.

Classes IPC  ?

• B01D 59/26 - Séparation par extraction par sorption, c.-à-d. absorption, adsorption, persorption
• B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique

Abrégé

The present invention relates to a biomarker composition for diagnosing exposure to fine dust, a detection method therefor, and a method for diagnosing exposure to fine dust by using same, and, more specifically, it was ascertained that a 2-naphthol level in urine increase as exposure to fine dust increases, so that a change in the 2-naphthol level in urine reflects exposure to polycyclic aromatic hydrocarbons, which is one of the main components of Korean fine dust, and thus a biomarker for diagnosing exposure to fine dust and identifying exposure amount can be provided. It was ascertained that a sample pretreatment process and an HPLC/FLD analysis condition according to the present invention resolve convenience and economic feasibility problems of conventional analysis methods so as to that a change in 1-naphthol or 2-naphthol level in non-invasive samples and urine is more accurately detected, and thus the sample pretreatment process and the HPLC/FLD analysis condition can be provided as a method for diagnosing exposure to fine dust.

Classes IPC  ?

• G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
• G01N 30/74 - Détecteurs optiques
• G01N 30/72 - Spectromètres de masse
• G01N 30/06 - Préparation

Abrégé

Lactobacillus acidophilusStreptococcus thermophilusStreptococcus thermophilus strains in a medium for intestinal beneficial bacteria and is substantially equivalent to fructooligosaccharide and galactooligosaccharide, which are representative prebiotics, in terms of functions thereof, and thus a prebiotic composition containing a pear extract as an active ingredient, a synbiotic composition comprising the prebiotic composition, and a functional food composition comprising the synbiotic composition are provided.

Classes IPC  ?

• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 19/00 - Produits à base de fruits ou de légumesLeur préparation ou leur traitement
• A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
• A23P 10/20 - AgglomérationGranulationMise en comprimés

Abrégé

The present invention relates to a method for providing information for the early diagnosis of colon cancer by using a biological sample in order to diagnose colon cancer. More specifically, excellent quantification of PhIP and MeIQx in terms of yield is achieved when a biological sample of urine is hydrolyzed with a strong alkali and then analyzed through liquid extraction, as compared to when the sample is hydrolyzed with an enzyme or a strong acid. Thus, a method that uses a strong alkali for hydrolyzing a sample and then liquid extraction may be provided as a diagnosis method for the effective and non-invasive early diagnosis of colon cancer using a biological sample.

Classes IPC  ?

• G01N 30/72 - Spectromètres de masse
• G01N 30/06 - Préparation
• G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes

Abrégé

The present invention relates to a biomarker composition for predicting the prognosis or determining the stage of chronic liver disease. The present invention performs a total RNA-seq analysis on tissues of patients with steatosis and non-alcoholic steatohepatitis, and identifies 38 genes that are specifically highly expressed during disease progression from steatosis to non-alcoholic steatohepatitis. The present invention selects genes showing a characteristic expression pattern, and constructs a classification model capable of distinguishing between steatosis and non-alcoholic steatohepatitis using the genes. As a result, the present invention verifies that steatosis and non-alcoholic steatohepatitis can be classified with high accuracy. Accordingly, the genes may be used as biomarkers for predicting the prognosis of chronic liver disease or as biomarkers for classifying steatosis and non-alcoholic steatohepatitis, and development of gene therapy or other drugs that inhibit the expression or activity of the genes may improve the effectiveness of treating chronic liver disease.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a survey-based wellness analysis system and a method therefor. According to the present invention, a wellness analysis method using a survey-based wellness analysis system comprises the steps of: receiving responses from users with respect to a wellness survey divided into eight areas; calculating area-specific total scores and exposure scores by adding response scores for each area; calculating a wellness score by using the area-specific total scores; and analyzing the degree of wellness by using the calculated area-specific total scores and wellness score, and providing the analyzed result to a user who has filled out the survey. According to the present invention, the degree of exposure of each user to a harmful substance can be checked on the basis of the survey divided into eight areas, and a solution that is suitable to the user can be provided by using the checked degree of exposure.

Classes IPC  ?

• G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
• G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p. ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé

Abrégé

The present invention relates to a music output apparatus using a sensor and a method thereof. According to the present invention, the music output apparatus using the sensor comprises: a sensor unit including any one of a pressure sensor, a gyro sensor, and an acceleration sensor; a gesture recognition unit for recognizing a user's gesture by using sensed data; a controller for changing pre-stored music or generating new music corresponding to the recognized gesture; and an output unit for outputting the changed music or the generated music. As described above, the music output apparatus using the sensor according to an embodiment of the present invention can be used for music therapy without constructing expensive equipment, and enables music to be easily produced and arranged, thereby arousing the interest of infants. In addition, people majoring in music can conveniently practice in perfect pitch or give an improvised performance while carrying the music output apparatus using the sensor according to an embodiment of the present invention.

Classes IPC  ?

• G10H 1/00 - Éléments d'instruments de musique électrophoniques
• G10G 1/02 - Indicateurs de note ou d'accord, fixes ou ajustables, pour clavier ou touches d'instrument à cordes

Abrégé

The present invention relates to a fluorescent probe for detecting NAD(P)H in mitochondria, and a detection method using same. A probe of the present invention exhibits high selectivity and sensitivity to NAD(P)H and emits strong red fluorescence in the presence of NAD(P)H. Therefore, the probe exhibits predominant accumulation in the mitochondria of living cells, is usable in the detection and quantification of NAD(P)H in the mitochondria, and can provide a selective image of the mitochondria in real time, thereby being effectively usable for biological pathway studies and the identification of pathological diagnoses and the like. In addition, the present invention can be used to differentiate cancer cells from normal cells on the basis of mapping of the intensity of NAD(P)H-dependent fluorescence in mitochondria.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G01N 21/76 - ChimioluminescenceBioluminescence
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/483 - Analyse physique de matériau biologique
• C07D 221/12 - Phénanthridines
• G01N 31/22 - Utilisation des réactifs chimiques
• C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
• C07C 381/00 - Composés contenant du carbone et du soufre et comportant des groupes fonctionnels non couverts par les groupes

Abrégé

The present invention relates to a method for preparing choline alfoscerate, usable as a food raw material, from phosphatidylcholine or lecithin, and a choline alfoscerate preparation method according to the present invention uses a specific reaction medium and a specific catalytic enzyme, thereby enabling a high purity choline alfoscerate to be effectively prepared. Particularly, the preparation method allows a mixed solvent of water and hexane, which have high substrate solubility and an extraction solvent usable in the preparation of food raw materials, to be used as a reaction medium, and enables high purity purification of choline alfoscerate by only using a layer separation process of the reaction medium, thereby enhancing the productivity of choline alfoscerate to be greater than that of a conventional enzymatic synthesis method, having, unlike a conventional chemical synthesis method and a conventional purification method, very simple purification, and enabling the preparation of choline alfoscerate which is usable as a food raw material. Specifically, lecithin is a raw material of fractionated lecithin used as a substrate in the preparation method and is an inexpensive raw material obtained as a by-product in a soybean oil refining process and the like, and thus is expected to be greatly helpful in the commercialization of the preparation method in the future. In addition, choline alfoscerate prepared by the method according to the present invention can be effectively usable as a material for foods, pharmaceuticals and the like for improving cognitive function in patients having had a stroke and having dementia such as Alzheimer's disease.

Classes IPC  ?

• C12P 13/00 - Préparation de composés organiques contenant de l'azote
• C12N 9/20 - Scission des triglycérides, p. ex. au moyen de lipase
• C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p. ex. dans un gel ou dans des fibres creuses
• C12N 11/08 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique le support étant un polymère synthétique
• A23L 29/00 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• C12P 9/00 - Préparation de composés organiques contenant un métal ou un atome autre que H, N, C, O, S ou un halogène

Abrégé

The present invention relates to a foreign language learning system, and a method for providing a foreign language learning service by using the same. The method for providing a foreign language learning service by using a foreign language learning system, according to the present invention, comprises the steps of: requesting, from a user terminal, an input of at least one piece of data for each of personal information data, environmental information data and context information data when a request for providing a foreign language learning sentence is received from the user terminal; grouping, by classification, the at least one piece of inputted data so as to generate a plurality of data groups, and using the inputted data so as to analyze a current situation of a user; extracting a plurality of hyponyms and a sentence pattern corresponding to the current situation from among a plurality of hyponyms and a plurality of sentence patterns included in a database; randomly selecting a word included in the extracted synonyms and the grouped data so as to insert the selected word into a place holder location of the extracted sentence pattern, and using a seed modular random algorithm so as to generate a final sentence; and providing the generated final sentence to the user terminal. The present invention can simultaneously provide a vivid foreign language learning service optimized to a user and induce interest in the user such that the user voluntarily learns a foreign language.

Classes IPC  ?

• G06Q 50/20 - Éducation
• G09B 19/06 - Langues étrangères
• G06F 17/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des fonctions spécifiques

Abrégé

The present invention relates to the use of teosinte branched 1, cycloidea and PCF transcription factors (TCPs) in shade avoidance. The present inventors confirmed that TCP proteins, such as TCP5, TCP13, and TCP17, are involved in shade avoidance through interaction with ATHB2, HAT3, and ATHB4. In addition, a plant in which TCP13 is overexpressed expresses genes necessary for a shade avoidance response although it is cultured in a normal condition, but not in a shade condition, which indicates that TCP13 is a main upstream regulator giving rise to a shade avoidance response in a shade condition. That is, as described above, the investigation of a role of TCP13 in shade avoidance may be usefully applied to the expansion of productivity and yield of crops.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a composition containing an ANKS1A protein expression or activation inhibitor as an active ingredient for preventing or treating cancer, and a method for screening for the composition, and by means of the present invention, a composition having a superb cancer prevention and treatment effect and a method allowing convenient screening of an anti-cancer agent can be provided.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Provided is a pharmaceutical composition for preventing or treating muscular dystrophy containing Psoralea corylifolia-derived bakuchiol as an active ingredient. The pharmaceutical composition is effective for stimulating myocyte regeneration and inducing differentiation into myocytes.

Classes IPC  ?

• A61K 36/487 - Psoralea
• A61K 31/05 - Phénols

Abrégé

The present invention relates to a biomarker composition for diagnosing the sensitivity to an anticancer agent in anticancer agent-resistant breast cancer, a diagnosis kit, a diagnosis method, or a pharmaceutical composition for promoting anticancer effects, wherein it is possible to help effective treatment of tumors by restoring the sensitivity to anticancer agents such as tamoxifen, etc. if the expression of LY6K is inhibited or miR-192-5p is suppressed in breast cancer cells. Also, it is possible to help effective treatment of tumors by restoring the sensitivity to anticancer agents such as tamoxifen, etc. if the expression of miR-500a-3p is induced or miR-500a-3p is applied in breast cancer cells.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12N 15/86 - Vecteurs viraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines

Abrégé

The present invention relates to a pharmaceutical composition for treating STK11-mutation cancer, containing, as an active ingredient, a material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1); an anticancer drug containing the composition as an active ingredient; and a method for screening STK11-mutation cancer therapeutic agent. It was first established that, of cancer cells in which various gene mutations are confirmed, an STK11-mutation cancer cell line, which is confirmed at high frequency, was treated with cardiac glycosides as a material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1), to significantly inhibit the growth of cancer cells. Therefore, the material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1) can be a target for treating STK11-mutation-derived cancer.

Classes IPC  ?

• A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to novel peptides and use thereof and more specifically is directed to a peptide with anti-inflammatory effect, a polynucleotide encoding the peptide, a pharmaceutical composition comprising the peptide or polynucleotide for preventing or treating inflammatory diseases, an anti-inflammatory drug, an over-the-counter (OTC) drug composition comprising the peptide for preventing or ameliorating inflammation, a health food composition for alleviating or ameliorating inflammation, a cosmetic composition for preventing or ameliorating inflammation, a method for treating inflammatory diseases, comprising administrating the pharmaceutical composition to the subject suspected of having inflammatory disease, a method for preparing a mimetic of the peptide and a method for designing the same.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 5/083 - Tripeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala
• C07K 5/09 - Tripeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
• C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
• C07K 5/072 - Dipeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p. ex. Asp, Glu, Asn
• C07K 5/068 - Dipeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
• A23L 1/305 - Aminoacides, peptides ou protéines 
• C07K 5/087 - Tripeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p. ex. Phe, Tyr
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

In order to determine epigenetic variations of autosomal dominant polycystic kidney disease and functional association therebetween, the present inventors have subjected individuals with polycystic kidney disease and without polycystic kidney disease to analysis through methylation profiling in random fashion of the genome as a whole. Interestingly, in PKD1 and other genes associated with ion transport and cell adhesion, there was hypermethylation in the gene-body region, and the expression of these genes was down-regulated in polycystic kidney disease. In particular, in PKD1, there was hypermethylation in the polycystic kidney disease gene-body region, and this was associated with MBD2 (methyl-CpG-binding domain 2) protein binding. In addition, DNA methylation inhibitor treatment was accompanied by up-regulation of PKD1 expression and caused a delay in cyst formation in MDCK (Madin-Darby Canine Kidney) cells. This therefore demonstrates that, in the present invention, hypermethylation of PKD1 and regulator genes associated with cyst formation plays a decisive role in cyst formation and shows that the present invention can be used in therapeutic applications for autosomal dominant polycystic kidney disease.

Classes IPC  ?

• A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

The present invention relates to novel peptides and use thereof and more specifically is directed to a peptide with anti-inflammatory effect, a polynucleotide encoding the peptide, a pharmaceutical composition comprising the peptide or polynucleotide for preventing or treating inflammatory diseases, an anti-inflammatory drug, an over-the-counter (OTC) drug composition comprising the peptide for preventing or ameliorating inflammation, a health food composition for alleviating or ameliorating inflammation, a cosmetic composition for preventing or ameliorating inflammation, a method for treating inflammatory diseases, comprising administrating the pharmaceutical composition to the subject suspected of having inflammatory disease, a method for preparing a mimetic of the peptide and a method for designing the same.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdrl) as an agent for treating cancer. More particularly, it relates to an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdrl for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdrl is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdrl recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdrl and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial-skin and preparation of blood vessels for transplantation.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61P 27/00 - Médicaments pour traiter les troubles des sens

Abrégé

The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation.

Classes IPC  ?

• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• C07K 11/00 - Depsipeptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present invention relates to an adipocyte differentiation medium composition and a method of differentiating preadipocytes into adipocytes using the same. The adipocyte differentiation medium composition is characterised in that it comprises insulin, DHEA (dehydroepiandrosterone) and histamine. Said medium composition achieves smoother distribution and more stable settling of differentiated adipocytes in comparison with conventional adipocyte differentiation medium compositions, thereby maximising adipocytic cell viability. Furthermore, the DHEA and histamine used in said medium composition is more cost-efficient than conventional adipocyte differentiation medium compositions that rely on dexamethasone and isobutylmethylxanthine.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

Disclosed herein is a method for producing a cyst-expressed transgenic animal using a PKD2 gene. The production method comprises preparing a PKD2 protein expression vector, inserting the expression vector into the nucleus of a fertilized egg to produce a PKD2 expression vector-containing fertilized egg, and transplanting the produced fertilized egg into the uterus of a surrogate mother. According to the invention disclosed herein, there is provided a method for producing transgenic animals, in which cysts are expressed only by the over express ion of the PKD2 gene. Also, transgenic mice are provided which can be effectively used in the investigation of cyst expression mechanisms and cyst control systems.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés